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Introduction: The BEACON study evaluated the efficacy and safety of QVA149, a once-daily 
dual bronchodilator containing a fixed-dose combination of the long-acting β
2
-agonist (LABA) 
indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), in 
development for the treatment of patients with chronic obstructive pulmonary disease (COPD), 
compared with the free-dose concurrent administration of indacaterol plus glycopyrronium 
(IND+GLY).
Methods: In this multicenter, double-blind, parallel group study, patients with stage II or stage III 
COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] 2010) were randomized 
(1:1) to once-daily QVA149 (110 µg indacaterol/50 µg glycopyrronium) or concurrent adminis-
tration of indacaterol (150 µg) and glycopyrronium (50 µg) via the Breezhaler® device (Novartis 
AG, Basel, Switzerland) for 4 weeks. The primary endpoint was to evaluate the noninferiority of 
QVA149 as compared with concurrent administration of IND+GLY, for trough forced expiratory 
volume in 1 second (FEV
1
) after 4 weeks of treatment. The other assessments included FEV
1
 
area under the curve from 0 to 4 hours (AUC
0–4 hours
) at day 1 and week 4, symptom scores, rescue 
medication use, safety, and tolerability over the 4-week study period.
Results: Of 193 patients randomized, 187 (96.9%) completed the study. Trough FEV
1
 at week 4 
for QVA149 and IND+GLY was 1.46 L ± 0.02 and 1.46 L ± 0.18, respectively. The FEV
1
 
AUC
0–4 hours
 at day 1 and week 4 were similar between the two treatment groups. Both treatment 
groups had a similar reduction in symptom scores and rescue medication use for the 4-week 
treatment period. Overall, 25.6% of patients in QVA149 group and 25.2% in the IND+GLY 
group experienced an adverse event, with the majority being mild-to-moderate in severity. No 
deaths were reported during the study or during the 30 days follow-up period.
Conclusion: The BEACON study demonstrated that once-daily QVA149 provides an efficacy 
and safety profile similar to the concurrent administration of its monocomponents indacaterol 
and glycopyrronium.
Keywords: COPD, LABA, LAMA, FEV
1
 AUC
0–4 hours
, rescue medication
Introduction
Current guidelines for the effective management of moderate-to-severe chronic 
 obstructive pulmonary disease (COPD) recommend the addition of a second long-
acting bronchodilator class to the existing bronchodilator regimen, thus combining a 
long-acting β
2
-agonist (LABA) with a long-acting muscarinic antagonist (LAMA).1 
Moreover, β
2
-agonists and muscarinic antagonists have a complementary  mechanism 
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Multicenter, randomized, double-blind, parallel-group study
Prerandomization Double-blind treatment period
Screening
period
Day −21 to
day −15
Day −14 to
day −1
Visit 3, 4 (day 1, 2) to visit 5, 6
(day 28, 29)
Visit 1 Visit 2 Visit 3randomization Visit 6
Visit 7
30-day follow-up
Run-in period
Indacaterol
150 µg od +
glycopyrronium
50 µg od
Indacaterol 150 µg od +
glycopyrronium 50 µg od
QVA149 110/50 µg od + placebo
Figure 1 BEACON study design.
Abbreviation: od, once daily.
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of action, and their combination has been shown to 
improve bronchodilation as compared with their respective 
monotherapies.2–8
The addition of a second bronchodilator has been seen 
to provide additional benefits in terms of enhanced broncho-
dilation, inspiratory capacity, improved dyspnea, quality of 
life, and a decline in rescue medication use.3,9 This concept 
of dual bronchodilation can currently be achieved with a 
free combination of a LABA and LAMA. However, the free 
LABA/LAMA combination requires the administration of the 
medications separately in different devices, and this would 
potentially affect patient convenience and compliance.10 
Thus, a fixed-dose LABA/LAMA combination would be a 
better treatment option.
Currently, there is no fixed-dose combination of LABA/
LAMA available for patients with COPD. QVA149, in 
development for the treatment of patients with COPD, is 
a once-daily dual bronchodilator containing a fixed-dose 
combination of the LABA indacaterol and the LAMA glyco-
pyrronium (NVA237). Both indacaterol and glycopyrronium 
have established safety and efficacy profiles,11–16 and are 
approved as once-daily monotherapies for the maintenance 
treatment of COPD. In addition, they both offer the benefit of 
being administered in the same Breezhaler® device (Novartis 
AG, Basel, Switzerland). Previous Phase III studies have 
demonstrated that QVA149 is safe and provides superior 
and clinically meaningful improvements in lung function 
compared with its monocomponents indacaterol 150 µg 
and glycopyrronium 50 µg, as well as tiotropium 18 µg and 
salmeterol/fluticasone 50/500 µg. These improvements in 
lung function were translated into  concomitant improvements 
in patient- reported outcomes (health status via St George’s 
Respiratory Questionnaire [SGRQ] and breathlessness via 
transition dyspnea index [TDI]) and a reduction in exacerba-
tions.17–21 QVA149 is thus expected to provide similar efficacy 
and safety as compared with the concurrent administration 
of its monocomponents.
In addition, the fixed-dose combination will offer a 
simplified and more convenient dosing regimen, compared 
with a free combination with the potential to improve patient 
compliance.
In the BEACON study, the efficacy and safety of once-
daily QVA149 was evaluated in comparison with the concur-
rent administration of its monocomponents – indacaterol and 
glycopyrronium – over a treatment period of 4 weeks.
Methods
Study design and treatment
This was a multicenter, double-blind, parallel-group, active-
controlled, noninferiority design to compare the efficacy of 
QVA149 110/50 µg versus concurrent administration of 
its monocomponents indacaterol (150 µg) and glycopyr-
ronium (50 µg) in patients with moderate-to-severe COPD 
 (Figure 1).22 The study consisted of a prerandomization 
period, which included screening/washout (7 days) and 
run-in period (14 days). To stabilize patients and standard-
ize baseline lung function, open-label, 150 µg of indacaterol 
and 50 µg of glycopyrronium were administered during the 
14-day run-in period. Patients were then randomized (1:1) 
to QVA149 and placebo or concurrent administration of 
indacaterol (IND) plus (+) glycopyrronium (GLY); all were 
administered via the Breezhaler® device.
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QVA149 versus the free combination of its monocomponents
To ensure that the fine-particle dose of indacaterol 
delivered to the lung from QVA149 matched that of the 
monotherapy, the dose of indacaterol was reduced from 
150 µg to 110 µg when given in the QVA149 fixed-dose 
combination. Pharmacokinetic data from previous inda-
caterol studies demonstrated the similarity of the steady-state 
systemic exposures of 150 µg of indacaterol and 50 µg of 
glycopyrronium to QVA149 (110/50 µg). Patients took their 
study medication (two capsules) concurrently, once daily, 
between 8–11 am.
Salbutamol (albuterol) was allowed as rescue medication. 
Inhaled corticosteroids (ICS) were allowed if the patients were 
on the stable ICS dose for at least 30 days prior to visit 1 and 
during the study. The protocol and procedures were approved 
by relevant institutional review boards and ethics committees. 
All participants provided written informed consent, and the 
study was designed in accordance with the International 
Conference on Harmonisation (ICH) Harmonised Tripartite 
Guidelines for Good Clinical Practice and with the ethical 
principles of the World Medical Association’s Declaration 
of Helsinki.
Patients
According to the Global initiative for chronic Obstructive 
Lung Disease (GOLD) 2010 guidelines, men and women 
were enrolled if they: were $40 years of age with moderate-
to-severe COPD (stage II or stage III); had post-bronchodi-
lator forced expiratory volume in 1 second (FEV
1
) $30% 
and ,80% of the predicted normal; post-bronchodilator 
FEV
1
/forced vital capacity (FVC) ,0.70; were current or 
ex-smokers, having a smoking history of at least ten pack-
years. In addition, all patients enrolled were symptomatic 
(coughing, wheezing, sputum production, breathlessness) 
according to daily electronic diary data, with a total symptom 
score of 1 or more (on a scale of 0 to 3) on at least 3 days 
prior to visit 3.
Key exclusion criteria included: patients with type I or 
uncontrolled type II diabetes; history of long QT syndrome 
or prolonged QTc; patients who had a COPD exacerbation 
that required treatment with antibiotics and/or oral cortico-
steroids and/or hospitalization in the 6 weeks prior to visit 1; 
patients who had a respiratory tract infection within 4 weeks 
prior to visit 1; and patients who had a clinically significant 
electrocardiogram abnormality.
end points and assessments
The primary endpoint was to evaluate the noninferior-
ity of QVA149 compared to concurrent administration of 
indacaterol plus glycopyrronium for trough FEV
1
 (mean of 
23 hours, 15 minutes and 23 hours, 45 minutes postdose) 
after 4 weeks of treatment in patients with moderate-to-severe 
COPD. The other assessments included FEV
1
 AUC
0–4 hours
 at 
day 1 and week 4, daily number of puffs of rescue medication 
use, e-diary data with recording of daily clinical symptoms 
on the scale of 0–3 (where 0 refers to no symptoms) over 
the study period of 4 weeks, and safety and tolerability 
(adverse events, laboratory tests, electrocardiograms, and 
vital signs).
Statistical method and analysis
The treatment difference between QVA149 and concur-
rent administration of indacaterol and glycopyrronium for 
trough FEV
1
 was estimated to be 0 mL after 4 weeks of 
treatment. Based on the treatment difference of 226 mL 
between QVA149 300/50 µg and placebo (lower limit of the 
95% confidence interval [CI] of 192 mL) in mean trough 
FEV
1
 in the QVA149A2204 study,23 the noninferiority 
margin of 100 mL was taken to be approximately one-half 
of this. Noninferiority was considered to be achieved if 
the lower bound values of two-sided 95% CI were greater 
than -100 mL.
A total of 154 evaluable patients would achieve 90% power 
with a one-sided noninferiority test at a significance level of 
2.5%. Approximately 184 randomized patients were required 
to adjust for an estimated combined attrition rate of 17%. The 
per protocol set was the primary analysis data set for this non-
inferiority study and included all patients in the full analysis 
set without any major protocol deviations.
The primary analysis was performed using a mixed model, 
with treatment as a fixed effect. Trough FEV
1
 measurement at 
baseline and FEV
1
 measurement prior and post to inhalation 
of short-acting bronchodilator were taken as covariates. This 
model also included smoking status (current/ex-smoker), 
history of inhaled corticosteroids at baseline as fixed effects, 
and center as random effects. Secondary analyses in terms of 
FEV
1
 AUC
0–4 hours
 at day 1 and week 4, daily number of puffs 
of rescue medication, and diary symptoms were performed 
using a similar mixed model (as per the primary endpoint) 
with the associated 95% CI. Secondary analyses were not 
statistically adjusted for multiplicity.
The safety set included all patients who received at least 
one dose of the study drug. The number (%) of patients with 
notable values of pulse rate of ,40 and .90 bpm, systolic 
blood pressure of ,90 and .140 mmHg, and diastolic blood 
pressure of ,50 and .90 mmHg was summarized. Notable 
QTc values and changes from baseline were summarized. 
A notable value was defined as a QTc interval of greater than 
450 milliseconds for both sexes at baseline and the number 
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Table 1 Demographics and clinical characteristics of patients at baseline
QVA149 (110/50 μg)  
N = 90
IND (150 μg) + GLY (50 μg) 
N = 103
Total 
N = 193
Age (years) 65.6 (7.28) 64.2 (7.40) 64.9 (7.36)
Sex, n (%)
 Male 58 (64.4) 59 (57.3) 117 (60.6)
 Female 32 (35.6) 44 (42.7) 76 (39.4)
Race, n (%)
 Caucasian 90 (100) 103 (100) 193 (100)
Pre-bronchodilator FEV1 (% predicted) 45.1 (12.88) 44.4 (12.95) 44.7 (12.89)
Post-bronchodilator FEV1 (% predicted) 54.1 (12.27) 53.8 (12.85) 54.0 (12.55)
FEV1 reversibility (% increase) 22.7 (16.78) 24.4 (19.47) 23.6 (18.24)
Duration of COPD (years) 7.3 (5.03) 6.8 (4.83) 7.0 (4.92)
Severity of COPD (GOLD 2010), n (%)
 Moderate 55 (61.1) 60 (58.3) 115 (59.6)
 severe 35 (38.9) 43 (41.7) 78 (40.4)
ICS use, n (%)
 no 29 (32.2) 39 (37.9) 68 (35.2)
 Yes 61 (67.8) 64 (62.1) 125 (64.8)
Smoking history, n (%)
 Ex-smoker 53 (58.9) 62 (60.2) 115 (59.6)
 Current smoker 37 (41.1) 41 (39.8) 78 (40.4)
Number of pack-years 41.6 (17.84) 39.2 (20.22) 40.3 (19.14)
Notes: All values in mean (SD) unless specified. FEV1 reversibility is calculated as % increase of FEV1 value after inhalation of bronchodilator. Pack-year is calculated by packs 
smoked per day × number of years as a smoker.
Abbreviations: InD+GLY, indacaterol and glycopyrronium; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; COPD, chronic obstructive pulmonary 
disease; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; SD, standard deviation.
Screened (N=320)
Randomized (N=193)
QVA149 110/50 µg
(n=90)
IND (150 µg) + GLY (50 µg)
(n=103)
Discontinued
• Administrative problems
• Adverse event(s)
• Protocol deviation
Completed
3 (3.3%)
2 (2.2%)
1 (1.1%)
0
87 (96.7%)
Discontinued
• Administrative problems
• Adverse event(s)
• Protocol deviation
Completed
3 (2.9%)
1 (1.0%)
1 (1.0%)
1 (1.0%)
100 (97.1%)
Figure 2 Patient disposition.
Abbreviation: InD+GLY, indacaterol and glycopyrronium.
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of newly occurring or worsening notable QTc values for 
postbaseline time points.
Results
Patients
Of the total 320 patients screened, 193 were  randomized 
and 187 (96.9%) completed the study (QVA149: 
N=87, IND+GLY: N=100) (Figure 2). The patient demo-
graphics and baseline characteristics were numerically com-
parable between the two treatment groups (Table 1).
Efficacy
Patients who were stable on the concurrent administration 
of indacaterol and glycopyrronium during the run-in period 
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QVA149
T
ro
u
g
h
 F
E
V
1 
(L
)
IND+GLY
−5 mL
(95% Cl, 5.1, 40.0)
1.4
1.6
0.8
1
1.2
0.4
0.6
0.2
0
n=81n=96
Figure 3 Trough FEV1 (L) at week 4.
Abbreviations: InD+GLY, indacaterol and glycopyrronium; FEV1, forced 
expiratory volume in 1 second; CI, confidence interval.
Week 4
T
ro
u
g
h
 F
E
V
1 
(L
)
Day 1
1.8
(95% Cl, 0.005; 0.54)
24 mL
IND+GLY QVA149
(95% Cl, 0.059; 0.034)
−12 mL
1.4
1.6
0.8
1
1.2
0.4
0.6
0.2
0
Figure 4 FEV1 AUC0–4 hours at day 1 and week 4.
Abbreviations: FEV1, forced expiratory volume in 1 second; AUC, area under 
curve; IND+GLY, indacaterol and glycopyrronium; CI, confidence interval.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
505
QVA149 versus the free combination of its monocomponents
continued to be stable when randomized to receive QVA149 
along with the free-dose concurrent administration of inda-
caterol and glycopyrronium, with similar maintenance of 
their lung function from day 1 to week 4 without any sig-
nificant difference. The least squares mean ± standard error 
(LSM ± SE) trough FEV
1
 at week 4 for QVA149 and for 
the free-dose combination of IND+GLY was 1.5 L ± 0.02 
and 1.5 L ± 0.18, respectively (Figure 3).
The FEV
1
 AUC
0–4 hours
 at day 1 and week 4 were similar for 
QVA149 in comparison with IND+GLY (Figure 4). Also, the 
FEV
1
 5 minutes to 4 hours postdose spirometry measurements 
at week 4 were similar between the two groups (Figure 5). 
Likewise, both groups had a similar reduction in symptom 
scores and rescue medication use from baseline for more 
than 4 weeks of treatment (Table 2).
The overall incidence of adverse events (AEs) was 
similar in both treatment groups, with 25.6% of patients 
experiencing an AE in the QVA149 group and 25.2% in the 
IND+GLY treatment group, with the majority of AEs being 
mild-to-moderate in severity. Nasopharyngitis and COPD 
worsening were the most frequently occurring AEs in both 
treatment groups (Table 3).
A similar number of patients had serious AEs in 
the IND+GLY treatment group (5.8%) compared with 
QVA149 group (4.4%). No patient discontinued the study 
medication due to a serious adverse event (SAE). There 
were no cardio- and cerebrovascular SAEs in either treat-
ment group.
Four patients in the IND+GLY group had notably 
increased QTc levels, compared with one patient in the 
QVA149 treatment group (Table 4). A total of six patients 
(6.7%) in the QVA149 group had AEs that were suspected to 
4 hours3 hours2 hours
Time postdose
F
E
V
1 
(L
)
1 hour30
      minutes
5
minutes  
2
QVA149 IND+GLY
1.5
1
0.5
0
Figure 5 FEV1 for the first 4 hours at week 4.
Abbreviations: InD+GLY, indacaterol and glycopyrronium; FEV1, forced 
expiratory volume in 1 second.
be study drug-related, compared with two patients (1.9%) in 
the indacaterol and glycopyrronium group. No deaths were 
reported in either treatment group during the study or during 
the 30-day follow-up period.
Discussion
The BEACON study directly compared the efficacy and 
safety of the fixed and the free combination of a LABA 
with a LAMA. The study met its primary objective to prove 
QVA149 as noninferior to the concurrent administration 
of indacaterol and glycopyrronium for its effect on trough 
FEV
1
 after 4 weeks of treatment. QVA149 also improved 
other clinical endpoints and had a safety and tolerability 
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Table 2 Daily total symptom score and rescue medication use over 4 weeks
Treatment n Baseline 
mean (SE)
LS mean SE Comparison Treatment difference
LS mean SE 95% CI
Change from baseline in the daily total symptom score
QVA149 (110/50 µg) (N = 84) 84 5.25 (0.275) -0.42 0.140 QVA149 –  
(InD+GLY)
0.07 0.161 (-0.24, 0.39)
InD (150 µg) + glY (50 µg) (N = 97) 95 5.74 (0.295) -0.49 0.130
Change from baseline in the mean daily number of puffs of rescue medication
QVA149 (110/50 µg) (N = 84) 84 2.24 (0.266) -0.45 0.124 QVA149 –  
(InD+GLY)
-0.04 0.159 (-0.35, 0.28)
InD (150 µg) + glY (50 µg) (N = 97) 95 2.04 (0.265) -0.42 0.113
Abbreviations: InD+GLY, indacaterol and glycopyrronium; LS mean, least squares mean; SE, standard error; CI, confidence interval.
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Table 3 Most frequent AEs (at least 1% in any treatment group) 
by preferred term of patients
QVA149  
(110/50 μg) 
N = 90 
n (%)
IND (150 μg) + 
GLY (50 μg) 
N = 103 
n (%)
Patients with any AE(s) 23 (25.6) 26 (25.2)
Preferred term
 Nasopharyngitis 7 (7.8) 6 (5.8)
 COPD worsening 4 (4.4) 2 (1.9)
 Cough 4 (4.4) 2 (1.9)
 Chest discomfort 2 (2.2) 0
 Influenza 2 (2.2) 1 (1.0)
 Myalgia 2 (2.2) 0
 Pneumonia 2 (2.2) 0
 Aortic aneurysm 1 (1.1) 0
 Breast pain 1 (1.1) 0
 Depression 1 (1.1) 0
 Diarrhea 1 (1.1) 1 (1.0)
 Dysphonia 1 (1.1) 1 (1.0)
 Dyspnea 1 (1.1) 2 (1.9)
 headache 1 (1.1) 1 (1.0)
 Ligament injury 1 (1.1) 0
Abbreviations: InD+GLY, indacaterol and glycopyrronium; AEs, adverse events; 
COPD, chronic obstructive pulmonary disease.
Table 4 Number (%) of patients with newly occurring or 
worsening notable QTc values (according to Fridericia’s formula) 
and maximum increase from baseline on study treatment
According to  
Fridericia’s formula
QVA149  
(110/50 μg)  
N = 90 
n/N (%)
IND (150 μg) + 
GLY (50 μg)  
N = 103 
n/N (%)
QTc . 450 ms 1/89 (1.1) 4/102 (3.9)
QTc . 480 ms 0/89 0/102
QTc . 500 ms 0/89 0/102
Maximum increase from baseline
 30–60 ms 0/84 4/101 (4.0)
 .60 ms 0/84 0/101
Abbreviations: InD+GLY, indacaterol and glycopyrronium; ms, milliseconds.
profile that was similar to the concurrent administration of 
its monocomponents indacaterol and glycopyrronium.
There have been studies demonstrating the combina-
tion of different classes of bronchodilators to improve 
efficacy without compromising safety in patients whose 
symptoms are not adequately controlled by bronchodilator 
monotherapy.3,6,7,24 This is due to the fact that LABAs and 
LAMAs are known to have a complementary mode of action, 
especially in terms of bronchodilation. LABAs augment the 
bronchodilatory effect produced by LAMAs by decreasing 
the release of acetylcholine via modulation of cholinergic 
neurotransmission. Moreover, LAMAs antagonize the effects 
of acetylcholine, amplifying the bronchodilation caused 
by LABAs. It has also been observed in previous studies 
that concurrent administration of a LABA with a LAMA 
produces superior bronchodilation in comparison with 
the  monotherapies, with additional benefits of reductions in 
dyspnea, dynamic hyperinflation, improved symptoms, and 
exercise endurance. QVA149 has been found to be effica-
cious and well-tolerated in comparison with indacaterol, 
glycopyrronium, tiotropium, salmeterol/fluticasone, and 
placebo in previous Phase III clinical trials.4,7,25 In the present 
study, QVA149 provided similar efficacy in terms of trough 
FEV
1
 and FEV
1
 AUC
0–4 hours
 as compared with IND+GLY, 
along with providing the advantage of dual bronchodilation 
in a single inhaler device. Also, peak FEV
1
 values revealed 
that the maximum improvements seen with the lung func-
tion were similar in both treatment groups. The symptomatic 
improvements achieved by patients in the QVA149 treatment 
group reinforced the association between improvements in 
lung function with other clinical outcomes.5,26
ICS are recommended for patients with severe COPD 
and recurrent exacerbations. However, in the real world set-
ting, patients with COPD are often inappropriately treated 
with ICS in combination with a LABA, irrespective of their 
GOLD classification.27 In the present study, 65% of the study 
population (60% had moderate and 40% had severe COPD) 
were on ICS at baseline. The BEACON study targeted this 
segment of patients with moderate-to-severe COPD for 
achieving more effective bronchodilation, symptom control, 
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QVA149 versus the free combination of its monocomponents
and reduced requirements for rescue medication with a fixed-
dose LABA/LAMA combination.
Although safety was not a primary objective of the 
study, it was important to demonstrate that there was no 
difference in the safety profile between the fixed-dose com-
bination QVA149 and the free combination therapy with 
indacaterol plus glycopyrronium. Overall, the incidence 
of AEs reported was numerically similar in both of the 
treatment groups, with no additional safety concerns for 
either the fixed- or free-dose combination. The results were 
consistent with the previous clinical studies that assessed 
the cardiac safety of QVA149,17–20,28 confirming that no 
significant cardiovascular safety concerns were observed 
with QVA149.
Patients with COPD have several comorbidities and are 
likely to be on other medications.29 Also, physical decon-
ditioning due to hyperinflation and cognitive impairment 
would make the use of multiple inhalers difficult for these 
patients.10 In comparison to the free-dose combinations, 
QVA149 provides the advantage of delivering the LABA/
LAMA combination in a single inhaler device, and thus 
aims to simplify the treatment regimen, improving patient 
adherence.10
Conclusion
The BEACON study demonstrated that once-daily QVA149 
improves lung function and symptom scores, reduces rescue 
medication use, and has a safety and tolerability profile 
similar to the free combination of its monocomponents ie, 
indacaterol and glycopyrronium. This study provides reassur-
ance that the LABA/LAMA fixed-dose combination QVA149 
provides benefits of dual bronchodilation in a single device, 
making it a more convenient treatment option for patients 
with COPD.
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